Intellia Therapeutics Claimed Company
Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patientsā diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. read more
HR or Marketing? Claim Your Free Employer Account
Birgit Schultes ā Vice President, Ex Vivo Cell Therapy at Intellia Therapeutics
Executive Bio
Birgit Schultes serves as the Vice President, Immunology (eXtellia Division) of Intellia Therapeutics, Inc.. Birgit started at Intellia Therapeutics, Inc. in September of 2017. Birgit currently resides in the Greater Boston Area.
Executive Team Culture Ratings from Intellia Therapeutics Employees
TOP
30%
Intellia Therapeutics' Executive Team scores in the Top 30%
of similar sized companies on Comparably
of similar sized companies on Comparably
Not Enough Ratings To Show Who Ranks Executive Team the Highest
Anonymously rate my experience at Intellia TherapeuticsNot Enough Ratings To Show Who Ranks Executive Team the Lowest
Anonymously rate my experience at Intellia TherapeuticsIntellia Therapeutics' Executive Team at a Glance
Based on 10 ratings, Intellia Therapeutics' employees are satisfied with their Executive Team and give them a āBā or 73/100.
Intellia Therapeutics' Executive Team ranks in the Top 35% of other companies in Boston and Top 30% of other companies on Comparably that also have 201-500 Employees.
×